<DOC>
	<DOCNO>NCT01641042</DOCNO>
	<brief_summary>The purpose study investigate immunogenicity , reactogenicity safety new meningococcal vaccine 134612 subject increase risk meningococcal disease compare activity healthy subject .</brief_summary>
	<brief_title>Comparison GlaxoSmithKline ( GSK ) 134612 Subjects With Increased Risk Meningococcal Disease Versus Healthy Subjects</brief_title>
	<detailed_description>For risk subject enrol , age-matched healthy subject enrol . Age matching perform accord follow age stratum : 1-5 year , 6-10 year , 11-17 year .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] comply requirement protocol . A male female 1 17 year age time first vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject inform assent obtain subject , appropriate , prior enrolment . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject practice adequate contraception one month ( 30 day ) prior first vaccine dose , negative pregnancy test day vaccination , agree continue adequate contraception administration first vaccine dose 2 month administration second vaccine dose . Additional inclusion criterion Atrisk group • Subjects increase risk meningococcal disease , anatomic asplenia degree functional asplenia complement deficiency . Additional inclusion criterion Healthy group Healthy subject establish medical history clinical examination enter study . Agematched subject Atrisk group accord age stratum 15 year , 610 year 11 17 year . Child care . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period ( phone contact Month 8 ) . Planned administration/administration vaccine foreseen study protocol period start 30 day administration study vaccine dose 30 day administration study vaccine dose . Administration license inactivated influenza vaccine allow per local recommendation . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . History meningococcal disease . Any confirm suspected Human Immunodeficiency Virus ( HIV ) infection , base medical history physical examination . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine one month second dose study vaccine . History reaction hypersensitivity likely exacerbate component vaccine include latex . Major congenital defect . History neurological disorder seizure , include GuillainBarré syndrome ( GBS ) . History simple , single febrile seizure permit . Acute disease and/or fever time enrolment . Pregnant lactate female . History chronic alcohol consumption and/or drug abuse . Female plan become pregnant planning discontinue contraceptive precaution . Additional exclusion criterion Atrisk group • Vaccination meningococcal disease serogroup within last 3 year subject young 7 year . within last 5 year subject 7 year old . Additional exclusion criterion Healthy group Vaccination meningococcal disease serogroup polysaccharide conjugate vaccine within last 5 year . Chronic administration immunosuppressant immunemodifying drug within 6 month prior first vaccine dose . Family history congenital hereditary immunodeficiency . Any confirm suspected immunosuppressive immunodeficient condition . Serious chronic illness . History asplenia hyposplenia complement deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Vaccines , conjugate</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Immunocompromised patient</keyword>
</DOC>